Zentalis Pharmaceuticals to Participate in Upcoming Investor Conference

SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Zentalis® Pharmaceuticals, Inc. (Nasdaq: ZNTL), a clinical oncology innovator advancing late-stage development of investigational first-in-class WEE1 inhibitor azenosertib as a biomarker-driven treatment approach for ovarian cancer, today announced that members of the management team will participate in a fireside discussion during Guggenheim's Emerging Outlook: Biotech Summit 2026 on February 11th in New York, NY at 3:30 p.m. ET. Access to a live webcast of the ...